# Translating Neuroprediction Into Precision Medicine Via Brain Priming

> **NCT03370510** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 5 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Oxytocin
- **BEHAVIORAL:** Pivotal Response Treatment
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03370510
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-07
- **Primary completion:** 2021-07-28
- **Final completion:** 2021-07-28
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Covid-19 Pandemic
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370510, "Translating Neuroprediction Into Precision Medicine Via Brain Priming". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03370510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*